Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker SNY · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Nov 10, 2026 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050627 ↗ |
| Jul 24, 2026 | AVAPRO IRBESARTAN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA020757 ↗ |
| Jul 9, 2026 | SARCLISA ESCENA ISATUXIMAB-IRFC | SNY Sanofi-Aventis U.S. LLC | Biologic (BLA) Type 3 - New Dosage Form | BLA761445 ↗ |
| Jun 26, 2026 | SARCLISA ISATUXIMAB-IRFC | SNY Sanofi Aventis US | Biologic (BLA), supplement Labeling | BLA761113 ↗ |
| Mar 12, 2026 | SOLIQUA 100/33 INSULIN GLARGINE; LIXISENATIDE | SNY Sanofi-Aventis US | Biologic (BLA), supplement Labeling | BLA208673 ↗ |
| Mar 12, 2026 | ADLYXIN LIXISENATIDE | SNY Sanofi-Aventis US | Biologic (BLA), supplement Labeling | BLA208471 ↗ |
| Feb 11, 2026 | AUBAGIO TERIFLUNOMIDE | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA202992 ↗ |
| Feb 2, 2026 | PRIMAQUINE PHOSPHATE PRIMAQUINE PHOSPHATE | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA008316 ↗ |
| Jan 27, 2026 | CAPRELSA VANDETANIB | SNY Genzyme Corp | New drug (NDA), supplement Labeling | NDA022405 ↗ |
| Jan 27, 2026 | PRIFTIN RIFAPENTINE | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA021024 ↗ |
| Jan 12, 2026 | CEREZYME IMIGLUCERASE | SNY Genzyme | Biologic (BLA), supplement Efficacy | BLA020367 ↗ |
| Dec 5, 2025 | RIFATER ISONIAZID; PYRAZINAMIDE; RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050705 ↗ |
| Dec 5, 2025 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050627 ↗ |
| Dec 5, 2025 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050420 ↗ |
| Oct 8, 2025 | RIFATER ISONIAZID; PYRAZINAMIDE; RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050705 ↗ |
| Oct 8, 2025 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050627 ↗ |
| Oct 8, 2025 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050420 ↗ |
| Sep 23, 2025 | CAPRELSA VANDETANIB | SNY Genzyme Corp | New drug (NDA), supplement REMS | NDA022405 ↗ |
| Aug 29, 2025 | WAYRILZ RILZABRUTINIB | SNY Genzyme Corp | New drug (NDA) Type 1 - New Molecular Entity | NDA219685 ↗ |
| Aug 1, 2025 | AVALIDE HYDROCHLOROTHIAZIDE; IRBESARTAN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA020758 ↗ |
| Aug 1, 2025 | AVAPRO IRBESARTAN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA020757 ↗ |
| Jun 26, 2025 | CAPRELSA VANDETANIB | SNY Genzyme Corp | New drug (NDA), supplement REMS | NDA022405 ↗ |
| Jun 11, 2025 | HECTOROL DOXERCALCIFEROL | SNY Sanofi | New drug (NDA), supplement Efficacy | NDA020862 ↗ |
| May 28, 2025 | SOLIQUA 100/33 INSULIN GLARGINE; LIXISENATIDE | SNY Sanofi-Aventis US | Biologic (BLA), supplement Labeling | BLA208673 ↗ |
| May 28, 2025 | ADLYXIN LIXISENATIDE | SNY Sanofi-Aventis US | Biologic (BLA), supplement Labeling | BLA208471 ↗ |
| May 14, 2025 | CAPRELSA VANDETANIB | SNY Genzyme Corp | New drug (NDA), supplement Labeling | NDA022405 ↗ |
| Mar 28, 2025 | QFITLIA FITUSIRAN SODIUM | SNY Genzyme Corp | New drug (NDA) Type 1 - New Molecular Entity | NDA219019 ↗ Letter or label ↗ |
| Mar 10, 2025 | PRIMAQUINE PHOSPHATE PRIMAQUINE PHOSPHATE | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA008316 ↗ |
| Feb 14, 2025 | MERILOG INSULIN ASPART-SZJJ | SNY Sanofi-Aventis U.S. LLC | Biologic (BLA) UNKNOWN | BLA761325 ↗ |
| Feb 5, 2025 | RIFATER ISONIAZID; PYRAZINAMIDE; RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050705 ↗ |
| Jan 2, 2025 | Synvisc, Synvisc-One Acid, hyaluronic, intraarticular | SNY Sanofi Genzyme Corp. | Device approval (PMA), supplement Special (Immediate Track) | P940015 ↗ |
| Dec 30, 2024 | LUMIZYME ALGLUCOSIDASE ALFA | SNY Genzyme | Biologic (BLA), supplement Labeling | BLA125291 ↗ |
| Dec 20, 2024 | XENPOZYME OLIPUDASE ALFA-RPCP | SNY Genzyme Corp | Biologic (BLA), supplement Labeling | BLA761261 ↗ |
| Dec 19, 2024 | CEREZYME IMIGLUCERASE | SNY Genzyme | Biologic (BLA), supplement Labeling | BLA020367 ↗ |
| Nov 1, 2024 | SOLIQUA 100/33 INSULIN GLARGINE; LIXISENATIDE | SNY Sanofi-Aventis US | Biologic (BLA), supplement Labeling | BLA208673 ↗ |
| Nov 1, 2024 | ADLYXIN LIXISENATIDE | SNY Sanofi-Aventis US | Biologic (BLA), supplement Labeling | BLA208471 ↗ |
| Oct 25, 2024 | SARCLISA ISATUXIMAB-IRFC | SNY Sanofi Aventis US | Biologic (BLA), supplement Efficacy | BLA761113 ↗ |
| Oct 25, 2024 | SARCLISA ISATUXIMAB-IRFC | SNY Sanofi Aventis US | Biologic (BLA), supplement Efficacy | BLA761113 ↗ |
| Oct 10, 2024 | RIFATER ISONIAZID; PYRAZINAMIDE; RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050705 ↗ |
| Oct 10, 2024 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050627 ↗ Letter or label ↗ |
| Oct 10, 2024 | RIFADIN RIFAMPIN | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA050420 ↗ Letter or label ↗ |
| Sep 20, 2024 | FEXINIDAZOLE FEXINIDAZOLE | SNY Sanofi | New drug (NDA), supplement Labeling | NDA214429 ↗ Letter or label ↗ |
| Sep 20, 2024 | FEXINIDAZOLE FEXINIDAZOLE | SNY Sanofi | New drug (NDA), supplement Labeling | NDA214429 ↗ Letter or label ↗ |
| Sep 20, 2024 | SARCLISA ISATUXIMAB-IRFC | SNY Sanofi Aventis US | Biologic (BLA), supplement Efficacy | BLA761113 ↗ |
| Aug 29, 2024 | TOUJEO, TOUJEO MAX, INSULIN GLARGINE U-300 MAX, INSULIN GLA… INSULIN GLARGINE RECOMBINANT | SNY Sanofi US Services | Biologic (BLA), supplement Labeling | BLA206538 ↗ |
| Jul 10, 2024 | FABRAZYME AGALSIDASE BETA | SNY Genzyme | Biologic (BLA), supplement Labeling | BLA103979 ↗ |
| Jul 10, 2024 | CEREZYME IMIGLUCERASE | SNY Genzyme | Biologic (BLA), supplement Labeling | BLA020367 ↗ |
| Jun 28, 2024 | ARAVA LEFLUNOMIDE | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA020905 ↗ |
| Jun 10, 2024 | AUBAGIO TERIFLUNOMIDE | SNY Sanofi Aventis US | New drug (NDA), supplement Labeling | NDA202992 ↗ |
| Jun 10, 2024 | KEVZARA SARILUMAB | SNY Sanofi Synthelabo | Biologic (BLA), supplement Efficacy | BLA761037 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates